Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis

Company Overview

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

Key Stats

• Today's Range: $0.09 to $0.11
• 50-Day Range: $0.06 to $0.13
• 52-Week Range: $0.06 to $0.24
• Volume: 18,226 shs
• Average Volume: 117,013 shs
• Market Capitalization: $8.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ENZN Stock Analysis - Frequently Asked Questions

How have ENZN shares performed this year?

Enzon Pharmaceuticals' stock was trading at $0.1561 at the beginning of 2025. Since then, ENZN stock has decreased by 26.4% and is now trading at $0.1149.

How were Enzon Pharmaceuticals' earnings last quarter?

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) posted its quarterly earnings results on Friday, May, 9th. The biotechnology company reported ($0.01) EPS for the quarter.

How do I buy shares of Enzon Pharmaceuticals?

Shares of ENZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Enzon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enzon Pharmaceuticals investors own include Biocept (BIOC), Aeterna Zentaris (AEZS), Energy Transfer (ET), DURECT (DRRX), Nymox Pharmaceutical (NYMX), OpGen (OPGN) and BioCryst Pharmaceuticals (BCRX).

Company Calendar

• Last Earnings: 5/09/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:ENZN
• Previous Symbol: NASDAQ:ENZN
• CIK: 727510
• Web: www.enzon.com
• Phone: (732) 980-4500
• Fax: 732-980-4585
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $780 thousand
• Net Margins: N/A
• Pretax Margin: 1,150.00%
• Return on Equity: -22.19%
• Return on Assets: -1.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 82.17
• Quick Ratio: 82.17

Sales & Book Value

• Annual Sales: $30 thousand
• Price / Sales: 284.22
• Cash Flow: $0.01 per share
• Price / Cash Flow: 10.96
• Book Value: $0.04 per share
• Price / Book: 2.87

Miscellaneous

• Outstanding Shares: 74,210,000
• Free Float: 73,918,000
• Market Cap: $8.53 million
• Optionable: Not Optionable
• Beta: 0.36